ADXS11-001 for orphan drug designation

Advaxis submitted ADXS11-001 (formerly known as Lovaxin-C) to the FDA for orphan drug designation to treat invasive carcinoma of the cervix.  The company’s technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein.

ADXS11-001 is a therapeutic vaccine that treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection.

For more information visit